NETWORK-1 TECHNOLOGIES Business Summary

Network-1 Technologies, Inc. (NTIP) operates as an intellectual property (IP) licensing and monetization firm, generating revenue primarily through licensing fees, royalties, and litigation settlements derived from its diverse patent portfolios. The company’s business model centers on the acquisition and enforcement of high-quality patents across several technology segments, including the Cox Portfolio (automated content recognition), the M2M/IoT Portfolio (eSIM and 5G technologies), and the High-Frequency Trading (HFT) Portfolio. While historically reliant on its Remote Power Patent for Power over Ethernet (PoE) technology, which generated over $188 million in cumulative revenue, the company has recently pivoted toward active litigation and licensing efforts in the IoT and HFT sectors, including high-profile suits against Samsung and Optiver. Network-1 competes in the specialized IP licensing market against firms such as Acacia Research Corporation, VirnetX Holding Corp, InterDigital, and ParkerVision, positioning itself as a micro-cap specialist that leverages a lean operational structure to maximize shareholder returns through a consistent dividend policy. The leadership team is led by Chairman and CEO Corey M. Horowitz, who has spearheaded the company’s strategic direction since 2003 and maintains a significant insider ownership stake of approximately 26%. Supporting the executive suite are Chief Financial Officer Robert M. Mahan, appointed in late 2022 with extensive experience in financial consulting and operations, and Executive Vice President Jonathan M. Greene, who has overseen technical and marketing analysis for the IP portfolios since 2013. The company’s governance is further stabilized by a board that includes Allison Hoffman and Niv Harizman, both re-elected in late 2025. Network-1 maintains a strong institutional investor base, with notable positions held by Cannell Capital LLC—which disclosed a 5% stake in early 2026—as well as Clayton Partners LLC and Renaissance Technologies. Additionally, the company holds a strategic equity investment in ILiAD Biotechnologies, providing exposure to the life sciences sector beyond its core IP enforcement activities.